Roger Song
Stock Analyst at Jefferies
(4.29)
# 373
Out of 5,148 analysts
54
Total ratings
52.17%
Success rate
20.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Buy | $75 | $46.48 | +61.36% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $20.88 | +196.93% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $261.16 | +42.06% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $92.68 | +27.32% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $17.52 | +139.73% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $68.75 | +76.00% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $32.85 | +36.99% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.60 | +86.05% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $500.04 | +12.79% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.32 | +278.79% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.93 | +1,723.25% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $31.48 | +14.38% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $45.90 | +17.65% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $7.17 | -16.32% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.26 | +378.09% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.93 | +78.34% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $13.56 | +91.74% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.46 | +230.97% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.03 | +131.40% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $64.42 | +38.16% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $9.60 | +160.42% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $15.42 | +165.89% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.37 | +43.62% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $59.85 | +115.54% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $5.09 | +57.17% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $100.29 | -3.28% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $32.60 | +237.48% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.18 | +737.32% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.67 | +237.08% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $19.14 | +997.18% | 1 | Sep 2, 2020 |
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $46.48
Upside: +61.36%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $20.88
Upside: +196.93%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $261.16
Upside: +42.06%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $92.68
Upside: +27.32%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $17.52
Upside: +139.73%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $68.75
Upside: +76.00%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $32.85
Upside: +36.99%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.60
Upside: +86.05%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $500.04
Upside: +12.79%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.32
Upside: +278.79%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.93
Upside: +1,723.25%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $31.48
Upside: +14.38%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $45.90
Upside: +17.65%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $7.17
Upside: -16.32%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.26
Upside: +378.09%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.93
Upside: +78.34%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.56
Upside: +91.74%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.46
Upside: +230.97%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.03
Upside: +131.40%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $64.42
Upside: +38.16%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $9.60
Upside: +160.42%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $15.42
Upside: +165.89%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $24.37
Upside: +43.62%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $59.85
Upside: +115.54%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $5.09
Upside: +57.17%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $100.29
Upside: -3.28%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $32.60
Upside: +237.48%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.18
Upside: +737.32%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $2.67
Upside: +237.08%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $19.14
Upside: +997.18%